PMID- 20151997
OWN - NLM
STAT- MEDLINE
DCOM- 20110321
LR  - 20181201
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 12
IP  - 3
DP  - 2010 Mar
TI  - Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in 
      patients at high risk for coronary heart disease with diabetes mellitus, 
      metabolic syndrome or neither.
PG  - 210-8
LID - 10.1111/j.1463-1326.2009.01152.x [doi]
AB  - AIM: Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are both 
      associated with increased risk for atherosclerotic coronary heart disease (CHD). 
      Thus, it is useful to know the relative efficacy of lipid-altering drugs in these 
      patient populations. METHODS: A double-blind, parallel group trial of adult 
      patients with hypercholesterolaemia at high-CHD risk receiving atorvastatin 40 
      mg/day compared atorvastatin 40 mg plus ezetimibe 10 mg (ezetimibe) vs. doubling 
      atorvastatin to 80 mg. This post hoc analysis reports lipid efficacy results in 
      patients grouped by diagnosis of T2DM, MetS without T2DM or neither. Per cent 
      change from baseline at week 6 was assessed for LDL-C, total cholesterol, HDL-C , 
      non-HDL-C , Apo A-I, Apo B and triglycerides. Safety was monitored through 
      clinical and laboratory adverse events (AEs). RESULTS: Compared with doubling 
      atorvastatin, atorvastatin plus ezetimibe resulted in greater reductions in 
      LDL-C, triglycerides, Apo B, non-HDL-C, total cholesterol and lipid ratios in the 
      T2DM, MetS and neither groups. Treatment effects were of similar magnitude across 
      patient groups with both treatments, except triglycerides, which were slightly 
      greater in the T2DM and MetS groups vs. neither group. Changes in HDL-C , Apo A-I 
      and high sensitivity C-reactive protein (hs-CRP) were comparable for both 
      treatments in all three groups. Safety and tolerability profiles were generally 
      similar between treatments and across patient groups, as were the incidence of 
      liver and muscle AEs. CONCLUSIONS: Compared with doubling atorvastatin to 80 mg, 
      addition of ezetimibe to atorvastatin 40 mg produced greater improvements in 
      multiple lipid parameters in high-CHD risk patients with T2DM, MetS or neither, 
      consistent with the significantly greater changes observed in the full study 
      cohort (clinical trial # NCT00276484).
FAU - Conard, S
AU  - Conard S
AD  - Family Practice, University of Texas Southwestern Medical School, Dallas, TX 
      75243, USA. sconard@med-edge.com
FAU - Bays, H
AU  - Bays H
FAU - Leiter, L A
AU  - Leiter LA
FAU - Bird, S
AU  - Bird S
FAU - Lin, J
AU  - Lin J
FAU - Hanson, M E
AU  - Hanson ME
FAU - Shah, A
AU  - Shah A
FAU - Tershakovec, A M
AU  - Tershakovec AM
LA  - eng
SI  - ClinicalTrials.gov/NCT00276484
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Azetidines)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Pyrroles)
RN  - A0JWA85V8F (Atorvastatin)
RN  - EOR26LQQ24 (Ezetimibe)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticholesteremic Agents/*administration & dosage
MH  - Atorvastatin
MH  - Azetidines/*administration & dosage
MH  - Canada
MH  - Coronary Artery Disease/drug therapy/*prevention & control
MH  - Diabetic Angiopathies/drug therapy/*prevention & control
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination/methods
MH  - Ezetimibe
MH  - Heptanoic Acids/*administration & dosage
MH  - Humans
MH  - Hypercholesterolemia/*drug therapy
MH  - Male
MH  - Metabolic Syndrome/complications/*drug therapy
MH  - Middle Aged
MH  - Pyrroles/*administration & dosage
MH  - Risk Factors
MH  - Treatment Outcome
MH  - United States
MH  - Young Adult
EDAT- 2010/02/16 06:00
MHDA- 2011/03/22 06:00
CRDT- 2010/02/16 06:00
PHST- 2010/02/16 06:00 [entrez]
PHST- 2010/02/16 06:00 [pubmed]
PHST- 2011/03/22 06:00 [medline]
AID - DOM1152 [pii]
AID - 10.1111/j.1463-1326.2009.01152.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2010 Mar;12(3):210-8. doi: 10.1111/j.1463-1326.2009.01152.x.